Search by Drug Name or NDC

    NDC 00067-2035-80 Excedrin 250; 250; 65 mg/1; mg/1; mg/1 Details

    Excedrin 250; 250; 65 mg/1; mg/1; mg/1

    Excedrin is a ORAL TABLET, COATED in the HUMAN OTC DRUG category. It is labeled and distributed by GlaxoSmithKline Consumer Healthcare Holdings (US) LLC. The primary component is ACETAMINOPHEN; ASPIRIN; CAFFEINE.

    Product Information

    NDC 00067-2035
    Product ID 0067-2035_edbb64b9-f8ba-48db-8a36-d5837114f822
    Associated GPIs 64990003200350
    GCN Sequence Number 040186
    GCN Sequence Number Description aspirin/acetaminophen/caffeine TABLET 250-250-65 ORAL
    HIC3 H3D
    HIC3 Description ANALGESIC/ANTIPYRETICS, SALICYLATES
    GCN 10414
    HICL Sequence Number 001807
    HICL Sequence Number Description ASPIRIN/ACETAMINOPHEN/CAFFEINE
    Brand/Generic Brand
    Proprietary Name Excedrin
    Proprietary Name Suffix Migraine Geltabs
    Non-Proprietary Name Acetaminophen, Asprin, Caffeine
    Product Type HUMAN OTC DRUG
    Dosage Form TABLET, COATED
    Route ORAL
    Active Ingredient Strength 250; 250; 65
    Active Ingredient Units mg/1; mg/1; mg/1
    Substance Name ACETAMINOPHEN; ASPIRIN; CAFFEINE
    Labeler Name GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
    Pharmaceutical Class Anti-Inflammatory Agents, Non-Steroidal [CS], Central Nervous System Stimulant [EPC], Central Nervous System Stimulation [PE], Cyclooxygenase Inhibitors [MoA], Decreased Platelet Aggregation [PE], Decreased Prostaglandin Production [PE], Methylxanthine [E
    DEA Schedule n/a
    Marketing Category NDA
    Application Number NDA020802
    Listing Certified Through 2024-12-31

    Package

    NDC 00067-2035-80 (00067203580)

    NDC Package Code 0067-2035-80
    Billing NDC 00067203580
    Package 1 BOTTLE in 1 CARTON (0067-2035-80) / 80 TABLET, COATED in 1 BOTTLE
    Marketing Start Date 2011-09-13
    NDC Exclude Flag N
    Pricing Information N/A

    Standard Product Labeling (SPL)/Prescribing Information SPL cc2f4a6f-2a27-4a60-b5ef-ae0bb0988ff8 Details

    Revised: 7/2021